VAGELOS P ROY
Known title: DirectorCIK: 0001013064
Associated companies
Transaction History
| REGN | ▼ Sell | Gift | 259 | $0 | 4/3/2023 | View on chart |
| REGN | ▼ Sell | Gift | 25,000 | $0 | 3/23/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 42,500 | $11.5M | 2/22/2023 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 29,005 | $21.8M | 2/22/2023 | View on chart |
| REGN | ▼ Sell | Gift | 291 | $0 | 1/4/2023 | View on chart |
| REGN | ▼ Sell | Other | 111 | $81K | 12/20/2022 | View on chart |
| REGN | ▼ Sell | Other | 30 | $22K | 12/20/2022 | View on chart |
| REGN | ▲ Buy | Grant | 1,651 | $0 | 12/16/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 57 | $43K | 12/9/2022 | View on chart |
| REGN | ▼ Sell | Gift | 304 | $0 | 10/3/2022 | View on chart |
| REGN | ▼ Sell | Gift | 357 | $0 | 7/5/2022 | View on chart |
| REGN | ▼ Sell | Gift | 23,077 | $0 | 5/24/2022 | View on chart |
| REGN | ▼ Sell | Gift | 302 | $0 | 4/6/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 14,286 | $10.0M | 3/30/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 14,286 | $10.0M | 3/30/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 48,103 | $31.5M | 3/14/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 75,000 | $13.4M | 3/14/2022 | View on chart |
| REGN | ▼ Sell | Gift | 338 | $0 | 1/4/2022 | View on chart |
| REGN | ▼ Sell | Other | 107 | $68K | 12/16/2021 | View on chart |
| REGN | ▼ Sell | Other | 19 | $12K | 12/16/2021 | View on chart |
| REGN | ▲ Buy | Grant | 1,861 | $0 | 12/8/2021 | View on chart |
| REGN | ▼ Sell | Gift | 347 | $0 | 10/4/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 75,000 | $13.4M | 8/25/2021 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 49,282 | $32.9M | 8/25/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 10,039 | $6.5M | 8/18/2021 | View on chart |
| REGN | ▼ Sell | Gift | 17,000 | $0 | 8/9/2021 | View on chart |
| REGN | ▼ Sell | Gift | 373 | $0 | 7/2/2021 | View on chart |
| REGN | ▼ Sell | Gift | 19,000 | $0 | 6/14/2021 | View on chart |
| REGN | ▼ Sell | Gift | 22,000 | $0 | 5/27/2021 | View on chart |
| REGN | ▼ Sell | Gift | 446 | $0 | 4/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.